Insulin (medication)

Lore & Background

Insulin as a medication originated from pancreatic extracts. Initially, insulin was obtained from animal pancreases—primarily cows and pigs—requiring up to two tons of pig parts to produce eight ounces of purified insulin. Purity improved steadily, reaching 99% by the mid-1970s via high-pressure liquid chromatography.

Reader's Guide

Insulin's significance lies in its life-saving role for millions with diabetes. It is a cornerstone of modern medicine, listed on the World Health Organization's Essential Medicines list. However, clinical experience has shown conflicting evidence on whether synthetic insulins are less allergenic, and the International Diabetes Federation states there is no overwhelming evidence to prefer one species over another. Early initiation of insulin therapy in type 2 diabetes offers benefits but also challenges, including gradual dose increases and risk of severe hypoglycemia, leading to hesitation among patients and doctors. Insulin's mechanisms are highly conserved across species, and its discovery transformed diabetes from a fatal diagnosis to a manageable chronic condition.

Did You Know?

• Insulin can be made from the pancreas of pigs or cows, or via recombinant technology using E. coli or Saccharomyces cerevisiae.
• Allergy to insulin affects about 2% of people, most reactions due to preservatives like zinc, protamine, or meta-cresol rather than insulin itself.
• Repeated injection without site rotation can cause lipohypertrophy and amyloidomas, which appear as firm nodules under the skin.

Two Diseases, Two Treatment Philosophies

Type 1 diabetes is an autoimmune condition in which the body destroys the insulin-producing beta cells of the pancreas. Without this hormone, cells cannot pull glucose from the bloodstream, and chronic hyperglycemia sets in, eventually damaging the kidneys, nerves, cardiovascular system, and other organs. The only treatment is regular insulin injections. Type 2 diabetes, far more common, follows a different trajectory: cells develop resistance to insulin, forcing the pancreas to overproduce the hormone. When that compensation finally breaks down, blood sugar climbs and the disease manifests. Treatment here is layered—dietary shifts toward low glycemic index foods, physical activity to restore insulin sensitivity, and medications that either boost insulin secretion, enhance organ-level insulin response, slow gastrointestinal glucose absorption, or promote glucose loss through urine. The choice of agent depends on the diabetes type, the patient's age, and individual circumstances, making treatment deeply personalized rather than one-size-fits-all.

The Insulin Spectrum: From Rapid to Ultra-Long Acting

Insulin preparations are distinguished primarily by how quickly they peak and how long they remain active in the body. Rapid-acting analogs such as insulin lispro (Humalog), insulin aspart (Novolog), and insulin glulisine (Apidra) reach their peak in roughly one hour before being metabolized. Short-acting options like regular insulin (Humulin R, Novolin R) and prompt insulin zinc (Semilente) peak between two and four hours. Intermediate-acting forms, including isophane insulin (NPH) and insulin zinc (Lente), peak between four and ten hours. Long-acting insulins—extended insulin zinc (Ultralente), insulin glargine (Lantus), insulin detemir (Levemir), and insulin degludec (Tresiba)—deliver roughly twenty-four hours of coverage, often without a pronounced peak. Degludec is sometimes set apart as ultra-long acting because its duration stretches to approximately forty-two hours. In acute care, insulin can be given intravenously, while routine administration is subcutaneous via injection or pump. A systematic review found no clear superiority among detemir, glargine, degludec, or NPH for nocturnal hypoglycemia, A1c, cardiovascular events, quality of life, or mortality, and no meaningful differences between adults and children.

Beyond Insulin: The Mechanistic Arsenal

For type 2 diabetes, clinicians have a pharmacological toolkit that extends well beyond insulin. Four principal mechanisms guide drug selection. Insulin sensitizers boost the responsiveness of cellular insulin receptors, directly tackling the resistance that defines the condition. Beta-cell stimulants nudge the pancreas to secrete more insulin. Alpha-glucosidase inhibitors slow the enzymatic breakdown of carbohydrates in the gut, reducing the speed of glucose absorption, while alpha-amylase inhibitors target starch digestion more broadly. SGLT2 inhibitors block the sodium-glucose transport protein 2 in the renal tubules, preventing glucose reabsorption and increasing its excretion in urine. These agents are frequently combined. As of 2020, the FDA had approved twenty-three unique antihyperglycemic drug combinations. The first triple oral combination—metformin, saxagliptin, and dapagliflozin—received approval in 2019, followed in 2020 by a second triple of metformin, linagliptin, and empagliflozin. GLP-1 receptor agonists like liraglutide, exenatide, tirzepatide, and pramlintide are typically given by injection, though semaglutide is notable for being available both as an injectable and as the oral pill Rybelsus.

Metformin's Singular Role and the Safety Legacy

Among the many oral agents for type 2 diabetes, metformin occupies a singular first-line position. As a biguanide, it reduces hepatic glucose output and enhances peripheral glucose uptake by skeletal muscle, typically lowering A1C by 1.5 to 2.0 percent. Crucially, it is the only widely used oral diabetic drug that does not cause weight gain, making it especially attractive for pediatric and adolescent patients, where it has become the most commonly prescribed agent. It may be the best choice for patients who also have heart failure. However, caution is required in those with impaired liver or kidney function, and the drug must be temporarily stopped before any radiographic procedure involving intravenous iodinated contrast due to an elevated risk of lactic acidosis. This safety concern is not new: phenformin, used from the 1960s through the 1980s, and buformin were both withdrawn for the same lactic acidosis risk. In pregnancy, most oral anti-diabetic agents are contraindicated, and insulin becomes the preferred treatment. An inhaled insulin formulation was briefly licensed but has since been withdrawn, leaving subcutaneous and intravenous routes as the standard.

Gallery